Sino-US Laekna (HKG: 2105) has successfully raised £791 million through an initial public offering (IPO) of 63,728,000 shares on the Hong Kong Stock Exchange, with each share priced at HKD12.41.
Company Background and Core Products
Founded in 2016, Laekna has established itself with two core products, both in-licensed from Swiss pharmaceutical giant Novartis, and an additional 14 pipelines. The company’s product portfolio includes LAE002, a competitive AKT inhibitor of Adenosine triphosphate (ATP), which is being developed to treat ovarian cancer, prostate cancer, breast cancer, and PD-1/PD-L1 drug-resistant solid tumors. The other core product, LAE001, is an androgen synthesis inhibitor under development for the treatment of prostate cancer.
Ongoing Clinical Studies and Regulatory Progress
A total of six clinical studies, including one regulatory study, are currently underway for Laekna’s products. These studies are crucial for advancing the company’s pipeline and bringing innovative treatments to market.-Fineline Info & Tech
